Sistema benchtop eProtein Discovery che integra espressione, purificazione e validazione di proteine per la drug discovery.
| Date | Round | Amount |
|---|---|---|
| Jan 2026 | Series C UK-based Nuclera added $12 million to its Series C, now at $87 million total, led by Elevage Medical Technologies and Jonathan Milner to accelerate antibody discovery. | $12M |
| Oct 2024 | Series C Cambridge biotech Nuclera raised a $75M Series C led by Elevage Medical Technologies to commercialise its eProtein Discovery protein-printing platform. | $75M |
| Jul 2022 | Series B Nuclera, a Cambridge biotech making a desktop protein bioprinter, raised an additional $15.5M Series B from M&G, Amadeus and others. | $15.5M |